Sumitomo Pharmaceuticals, Co., Ltd. announces that it has concluded a license agreement with Novo Nordisk A/S (Denmark) for the anti-diabetic agent, Repaglinide (generic name) which will enable Sumitomo Pharmaceuticals to develop and market the drug in Japan.